Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Cell Dev. Biol.

Sec. Cell Death and Survival

Volume 13 - 2025 | doi: 10.3389/fcell.2025.1673163

This article is part of the Research TopicMechanisms and Therapeutic Strategies in Cellular Injury and RepairView all 5 articles

ANXA1 and ARG2 Drive T Cell Proliferation in Ischemia-Reperfusion Injury: Integrated Bulk and Single-Cell Transcriptomic Analysis

Provisionally accepted
Haofeng  ZhengHaofeng ZhengKaiming  HeKaiming HeJianchao  WeiJianchao WeiWangtianxu  ZhouWangtianxu ZhouZhiyi  KongZhiyi KongQingfu  DaiQingfu DaiJieyi  DongJieyi DongZihuan  LuoZihuan LuoQiquan  SunQiquan Sun*
  • Department of Renal Transplantation, Guangdong Provincial People's Hospital, Guangzhou, China

The final, formatted version of the article will be published soon.

Ischemia-reperfusion injury (IRI) represents a common pathophysiological condition and serves as a shared mechanism underlying diverse critical diseases, including acute kidney injury, myocardial infarction, and stroke. T cells are increasingly recognized as central mediators of immune responses during IRI; however, the mechanisms governing their proliferation remain poorly characterized. Herein, an integrative analysis of bulk and single-cell transcriptomic datasets across multiple organ models was performed to investigate the role of T cell proliferation–related genes in IRI. We identified ANXA1 and ARG2 as key IRI-associated genes, both of which exhibited consistent upregulation during the early stages of injury. Immune infiltration analysis demonstrated that ANXA1 expression correlated most strongly with central memory CD4⁺ T cell infiltration, whereas ARG2 was linked to T helper 17 cell infiltration. Drug prediction and functional annotation further identified Hydrocortamate and NS6180 as potential therapeutic agents targeting T cell proliferation. Single-cell RNA sequencing not only confirmed the active involvement of T cells in IRI progression but also highlighted ANXA1 as a particularly prominent regulator. A renal IRI model was also used to further confirm altered T cell activity and differential expression of these key genes in vivo. Collectively, these findings elucidate the molecular mechanisms driving T cell proliferation in IRI, positioning ANXA1 and ARG2 as promising pan-organ IRI biomarkers and therapeutic targets for mitigating tissue damage and promoting repair.

Keywords: ischemia-reperfusion injury, T cell proliferation, ANXA1, ARG2, scRNA-sequencing

Received: 25 Jul 2025; Accepted: 25 Aug 2025.

Copyright: © 2025 Zheng, He, Wei, Zhou, Kong, Dai, Dong, Luo and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Qiquan Sun, Department of Renal Transplantation, Guangdong Provincial People's Hospital, Guangzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.